Delivery Order SPE2DB22D3011-SPE2DB25FQ2AJ
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $7,202.90 to AmerisourceBergen Drug Corp for the supply of Vyvanse 30 mg capsules (100 count) on July 30, 2025, with an ultimate completion date of July 31, 2025. This competitive, firm fixed-price delivery order carries no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The contract represents a child award under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $1,338.38 delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Vyvanse 30 mg capsules (100 count units). This is a firm fixed price contract with no set-aside designation, competitively awarded under AmerisourceBergen's existing pharmaceutical supply vehicle. The order is scheduled for completion by August 1, 2025, with performance occurring at the vendor's Conshohocken, Pennsylvania location, which serves as the company's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Vyvanse 60 mg capsules (100-count units) with a contract ceiling value of $1,378.96. This is a firm fixed-price delivery order with an ultimate completion date of August 6, 2025, and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was competitively procured with no set-aside designation....
- The Defense Logistics Agency awarded a delivery order valued at $1,241.46 to AmerisourceBergen Drug Corp for Vyvanse 40 mg capsules (100-count) on July 24, 2025, with an ultimate completion date of July 25, 2025. This firm fixed-price contract represents a competitively awarded, non-set-aside delivery order for pharmaceutical supply to support federal medical procurement needs. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Vyvanse 50 mg capsules (100-count units) with a contract value of $1,552.17. This competitively awarded, non-set-aside delivery order is structured as a firm fixed price contract with an ultimate completion date of July 23, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under...
- The Defense Logistics Agency awarded a delivery order valued at $1,238.84 to AmerisourceBergen Drug Corp for the supply of Vyvanse 40 mg capsules (100-count units) on July 24, 2025, with completion scheduled for July 25, 2025. This firm fixed-price delivery order represents a non-competitive set-aside award and is being performed at the contractor's Conshohocken, Pennsylvania location. The contract falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a $2,735.43 delivery order to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 10 mg on July 29, 2025, with completion scheduled for July 30, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is executed as a child order under AmerisourceBergen's larger prime contract vehicle. The pharmaceutical product will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Vyvanse 60 mg capsules (100-count units) under a firm fixed-price contract valued at $1,143.98. The delivery order, issued on August 1, 2025, with an ultimate completion date of August 4, 2025, represents a non-competitive award to the prime contractor. Performance will be executed from AmerisourceBergen's location in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Vyvanse 60 mg capsules (100-count units) under a firm fixed-price contract valued at $1,927.86. The order was competitively awarded without set-aside designation and is scheduled for completion by July 31, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform work at its corporate office location and serve as the prime contractor on this delivery order, which...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Vyvanse 50 mg capsules (100-count units) valued at $1,876.30 under a firm fixed price contract type. The award, issued on July 31, 2025, with an ultimate completion date of August 1, 2025, represents a non-competitive delivery order executed against AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's corporate office...
- SPE2DB22D3011Indefinite Delivery Contract
- SPE2DB22D3011-SPE2DB25FQ2AJDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,456.80 to AmerisourceBergen Drug Corp for the supply of Vyvanse 30 mg capsules (100-count units) on July 29, 2025, with an ultimate completion date of July 30, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract falls under AmerisourceBergen Drug Corp's broader Indefinite Delivery Contract (IDC) vehicle with DLA Troop Support Medical (designated SPE2DX), a comprehensive global pharmaceutical support contract valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical federal medical procurement vendor supporting military and veteran healthcare systems. The company's DLA IDC enables the supply of a comprehensive range of pharmaceutical products and medical supplies across multiple therapeutic domains to support Defense Health Agency operations and other federal healthcare customers. Vyvanse (lisdexamfetamine) is a controlled stimulant medication commonly utilized in military and federal healthcare settings for attention-deficit treatment, and this delivery order represents a routine pharmaceutical fulfillment under the company's established federal contract framework.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.5k | 7/29/25 |